I wanted to share something about @CelsiusOfficial ($CELH) that I learned a couple days ago when talking to a beverage industry expert.
I've been explaining over the past month that $CELH is transitioning from DTR (direct to retailer) to DSD (direct story delivery).
On the last earnings call the CEO of $CELH shared that they now have agreements with 150+ regional DSD partners. I've been wondering how they got to such a large number so quickly and I finally found out why.
Last year when $PEP acquired Rockstar for $3.8 billion they did so because they were locked up in an exclusive distribution agreement and it was the only way out. Rockstar is a dying brand but $PEP wanted some optionality.
Once the deal with Rockstar was finalized they approached BANG and offered to distribute for them. BANG said okay and then abandoned all their existing DSD partners that had supported them from the beginning. Those DSD companies now hate BANG for screwing them over.
These hundreds of DSD companies needed to fill that void left by BANG so they've been approaching $CELH.
This makes me even more bullish about $CELH because now they're working with the DSD partners that helped build BANG so fast.
I also heard a rumor that $PEP and BANG might sue each other because the rollout didn't go as well as promised.
Perhaps BANG is losing shelf space to $CELH and they want someone to blame rather than looking in the mirror or realizing that @CelsiusOfficial is a better product.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Just wrapped up calls with one of the $INTZ analysts as well as Investor Relations -- I'm still very bullish on $INTZ.
$INTZ is a $450M company with 2022 revenue estimates of $55-65M which means 150% top line growth with 70% gross margins.
Intro video:
$INTZ has done DoD work for 30+ years ($8-10 million per year) but now they are taking all of that data & expertise to launch an enterprise product called Shield.
Congrats to $TMDX for receiving the approval vote from the FDA panel hearing on OCS Heart 🚀 prnewswire.com/news-releases/…
Even though yesterday was a big day for $TMDX shareholders the bigger catalyst is still coming when $TMDX gets approval for DCD (donation after circulatory death) who.int/servicedeliver…
We also have OCS Liver approval on the horizon.
Because of all these catalysts Jason Mills from Canaccord Genuity raised his price target last month to $79 (more than 100% upside from current prices) streetinsider.com/Analyst+Commen…
I'm not sure who is selling $TMDX today but thank you for the gift because I'm buying your shares.
I'll keep betting on $TMDX because I've seen the competition and it sucks.
$TMDX OCS Heart vs. The Ice Cooler
$TMDX has their FDA panel hearing tomorrow; although these events are unpredictable I believe the data is overwhelming and $TMDX will eventually receive approval for DCD and DBD.
I would not be surprised if funds were selling their shares and/or shorting $TMDX to put pressure on the stock price so they could load up on call options. Don't get shaken out of your highest conviction companies.